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Introduction: Accumulating evidence suggests an important role for interleukin 17 (IL-17) in the pathogenesis of
several inflammatory diseases, including rheumatoid arthritis (RA) and psoriatic arthritis (PsA). Accordingly, clinical
trials aimed at blocking IL-17 have been initiated, but clinical results between patients and across different diseases
have been highly variable. The objective was to determine the variability in expression of IL-17A, IL-17F and their
receptors IL-17RA and IL-17RC in the synovia of patients with arthritis.
Methods: Synovial biopsies were obtained from patients with RA (n = 11), PsA (n = 15) and inflammatory osteoarthritis
(OA, n = 14). For comparison, synovia from noninflamed knee joints (n = 7) obtained from controls were included.
Frozen sections were stained for IL-17A, IL-17F, IL-17RA and IL-17RC and evaluated by digital image analysis. We used
confocal microscopy to determine which cells in the synovium express IL-17A and IL-17F, double-staining with CD4,
CD8, CD15, CD68, CD163, CD31, von Willebrand factor, peripheral lymph node address in, lymphatic vessel endothelial
hyaluronan receptor 1, mast cell tryptase and retinoic acid receptor–related orphan receptor γt (RORγt).
Results: IL-17A, IL-17F, IL-17RA and IL-17RC were abundantly expressed in synovial tissues of all patient groups.
Whereas IL-17RA was present mostly in the synovial sublining, IL-17RC was abundantly expressed in the intimal lining
layer. Digital image analysis showed a significant (P < 0.05) increase of only IL-17A in arthritis patients compared to
noninflamed control tissues. The expression of IL-17A, IL-17F and their receptors was similar in the different patient groups,
but highly variable between individual patients. CD4+ and CD8+ cells coexpressed IL-17A, and few cells coexpressed
IL-17F. IL-17A and IL-17F were not expressed by CD15+ neutrophils. Mast cells were only occasionally positive for IL-17A
or IL-17F. Interestingly, IL-17A and IL-17F staining was also observed in macrophages, as well as in blood vessels and
lymphatics. This staining probably reflects receptor-bound cytokine staining. Many infiltrated cells were positive for
the transcription factor RORγt. Colocalisation between RORγt and IL-17A and IL-17F indicates local IL-17 production.
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Conclusions: Increased expression of IL-17A is not restricted to synovial tissues of RA and PsA patients; it is also
observed in inflammatory OA. The heterogeneous expression levels may explain nonresponse to anti-IL-17 therapy in
subsets of patients.Introduction
Whereas initial studies focused mainly on type 1 helper
T (Th1) cells as having a prominent role in rheumatoid
arthritis (RA), subsequent studies suggested that Th17
cells also have an important role in this disease. The
functional role of this new type of effector helper T cell
has been studied extensively in recent years and shows
that it has important functions in the response to mi-
crobial infection and in promoting and maintaining
chronic inflammation and autoimmunity [1]. Interest-
ingly, recent studies have demonstrated the plasticity of
Th17 cells and have indicated their pathogenic role, es-
pecially when shifted towards Th1 cells [2-4].
Th17 cells were originally identified by their expression
of the proinflammatory cytokine interleukin 17 (IL-17)
and represent a distinct subset of CD4+ cells characterised
by the expression of Retinoic acid receptor–related or-
phan receptor γt (RORγt) [5]. The production of IL-17 is
specifically regulated by this transcription factor. The
cytokine IL-17 is formally referred to as IL-17A and is part
of a larger IL-17 cytokine family consisting of six members
ranging from IL-17A to IL-17F. The most studied family
members are IL-17A and IL-17F, which are mainly pro-
duced by Th17 cells to protect against extracellular
pathogens and fungi but also have proinflammatory
properties. IL-17 promotes the transcriptional activation
of proinflammatory cytokines, hematopoietic cytokines,
acute-phase response genes and antimicrobial mediators
[6], especially in synergy with other proinflammatory cyto-
kines such as tumour necrosis factor and IL-1β [7,8]. The
common receptor for the IL-17 Family members is IL-
17RA [9]. In addition to IL-17RA, IL-17RC is required for
signalling in response to IL-17A or IL-17F [10,11].
Levels of IL-17 have been found to be increased in the
synovial fluid and tissues of RA patients [12-14]. Further-
more, studies in several experimental animal models dem-
onstrated a detrimental role of IL-17 in arthritis [15-17].
IL-17−/− mice are resistant to collagen-induced arthritis
[18]. Therefore, it has been suggested that IL-17 may play
a crucial role in the pathogenesis of different forms of
arthritis by inducing synovial inflammation and promoting
bone destruction [19,20]. Accordingly, several clinical tri-
als targeting the IL-17 pathway in RA [21], psoriasis
[22,23], psoriatic arthritis (PsA) [24] and ankylosing spon-
dylitis [25] have been initiated (reviewed in [26]). Al-
though psoriasis patients show marked clinical benefit of
targeting IL-17A, the clinical response in RA and PsA hasbeen limited and variable between patients [27]. Conceiv-
ably, inhibiting IL-17 is only beneficial for those arthritis
patients with increased cytokine levels in the target tissue.
To provide more insight into the heterogeneity of the ex-
pression of IL-17 and IL-17 receptors at the site of inflam-
mation, we investigated the expression of IL-17A, IL-17F
and their receptors at the protein level in synovial tissues
from inflammatory arthritis patients.
Methods
Patients and synovial tissue collection
We included biological naïve patients with RA (according
to the American College of Rheumatology (ACR) 1987 cri-
teria [28], n = 11), PsA (Caspar criteria [29], n = 15) and in-
flammatory osteoarthritis (OA; according to the 1986 ACR
criteria for OA [30], n = 14). For research purposes all pa-
tients underwent miniarthroscopic synovial biopsy sam-
pling of an actively inflamed ankle or knee joint [31]. Six to
eight samples were collected for immunohistochemistry
(IHC) to correct for sampling error, as described previously
[32]. For comparison non-inflammatory controls (n = 7)
were included, patients who underwent orthopaedic arth-
roscopy for non-inflammatory joint pain. Table 1 shows the
demographic and clinical features. The study was approved
by the Institutional Review Board of the Academic Medical
Centre and performed according to the Declaration of
Helsinki. All study patients provided written informed
consent.
To ensure preservation of antigenic content [31,32],
synovial biopsy samples were snap-frozen en bloc in
Tissue-Tek O.C.T. compound (Sakura Finetek Europe,
Zoeterwoude, the Netherlands) immediately after collec-
tion and stored in liquid nitrogen. Synovial tissue biopsies
were cut into 5-μm sections and mounted on StarFrost ad-
hesive glass slides (Knittelgläser, Braunschweig, Germany),
after which slides were sealed in parafilm (Bemis, Neenah,
WI, USA) and stored at −80°C until further use.
Antibodies
To investigate the detailed expression pattern of IL-17
in synovium, tissue sections were stained using mouse
monoclonal antibodies against IL-17A (immunoglobulin
G1 (IgG1), clone 41802), IL-17F (IgG2a, clone 197315)
and their receptors IL-17RA (IgG1, clone 133617) and
IL-17RC (IgG2b, clone 309882), all from R&D Systems
(Minneapolis, MN, USA). For colocalisation studies, we
used antibodies against the transcription factor RORγt
Table 1 Demographic and clinical featuresa
Controls (n = 7) RA (n = 11) PsA (n = 15) OA (n = 14)
Age, yr 47 (40 to 60) 49 (45 to 62) 48 (34 to 56) 68 (54 to 77)
Females, n (%) 2 (29) 7 (64) 7 (47) 10 (71)
Disease duration, mo NA 18 (8 to 88) 41 (23 to 84)b 42 (13 to 72)c
Erosive disease, n (%) NA 3/8 (38) ND ND
RF-positive, n/total (%) NA 3/11 (27) ND ND
ACPA-positive, n (%) NA 4/7 (57) ND ND
VAS GDA NA 57 (55 to 85) 67 (54 to 75) ND
TJC28, n NA 9 (7 to 13) 2 (1 to 12) ND
SJC28 NA 11 (6 to 14) 2 (1 to 12) ND
ESR, mm/h NA 23 (16 to 47) 34 (8 to 56) ND
CRP, mg/L NA 24.3 (12.0 to 37.0) 11.0 (4.7 to 18.0) ND
DAS28 NA 5.46 (5.33 to 6.62) 4.67 (2.83 to 5.99) ND
NSAID use, n (%) NA 7 (64) 6 (40) 6 (67)d
MTX use, n (%) NA 6 (55) 10 (67) 0 (0)
aACPA, Anticitrullinated protein antibodies; CRP, C-reactive protein; DAS28, Disease Activity Score in 28 joints; ESR, Erythrocyte sedimentation rate; MTX, Methotrexate;
NA, Not applicable; ND, Not determined; NSAID, Nonsteroidal anti-inflammatory drug; OA, Osteoarthritis; PsA, Psoriatic arthritis; RA, Rheumatoid arthritis; RF, Rheumatoid
factor; SJC28, Swollen joint count of 28 joints; TJC28, Tender joint count of 28 joints; VAS GDA, Visual analogue scale (range from 0 to 100 mm) global disease activity.
bn = 1, cn = 6, dn = 5 with no data available. Data are presented as median (interquartile range).
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USA), T cells (biotin-conjugated mouse anti-CD4:
IgG1, clone RPA-T4; Biolegend, San Diego, CA, USA;
and biotin-conjugated mouse anti-CD8: IgG1, clone
RFT8; SouthernBiotech, Birmingham, AL), B cells
(biotin-conjugated mouse anti-CD19; IgG1, clone
HIB19; Biolegend), macrophages (biotin-conjugated
mouse anti-CD68; IgG2b clone Y1/82A; Biolegend;
and biotin-conjugated mouse anti-CD163; IgG1 clone
GHI/61; Biolegend), neutrophils (biotin-conjugated
mouse anti-CD15; IgM clone HI98; eBioscience, San
Diego, CA, USA), mast cells (mouse anti–mast cell
tryptase (MCT); IgG1 clone AA1; Dako, Glostrup,
Denmark), lymphatic vessels (goat polyclonal anti-
lymphatic vessel endothelial hyaluronan receptor 1
(Lyve-1); R&D Systems), blood vessels (mouse anti–
von Willebrand factor (vWF); IgG1 clone F8/86;
Dako) and high endothelial venules (mouse anti–
peripheral lymph node addressin (PNAd); IgM clone
MECA-79; Biolegend). Because some cell-specific
antibodies were of the same isotype as the IL-17A
antibody, we used a rabbit polyclonal IL-17A antibody
(Insight Biotechnology, Wembley, UK) to investigate
colocalisation with MCT, CD31 and vWF. During this
project, the anti-IL-17F antibody was removed from
the market and replaced with another mouse mono-
clonal anti-IL-17F antibody (IgG2b clone 197301;
R&D Systems). Colocalisation studies using both anti-
IL-17F antibodies showed that the antibodies almost
completely overlap.Immunohistochemistry
IHC was performed using a two-step immunoperoxidase
method followed by a biotin tyramide (PerkinElmer,
Waltham, MA, USA) enhancement step to detect IL-
17A, IL-17F and IL-17RA or followed by BrightVision
(Immunologic, Duiven, the Netherlands) to detect IL-
17RC. Sealed slides containing frozen sections were
thawed at room temperature for 30 minutes, unpacked,
and air-dried for another 20 minutes. Subsequently, sec-
tions were fixed in acetone, and endogenous peroxidase
activity was blocked with 0.3% H2O2 in 0.1% sodium
azide in phosphate-buffered saline (PBS) for 20 minutes.
After washing in PBS, primary antibodies were incubated
overnight at 4°C. As negative controls, irrelevant isotype-
matched immunoglobulins instead of the primary anti-
body were applied to the sections. The next day, staining
was developed using a goat anti-mouse horseradish per-
oxidase (HRP)–conjugated antibody (Dako), after which
the intensity was enhanced using biotinylated tyramide
(PerkinElmer) and streptavidin-HRP (Dako). Enhance-
ment of the IL-17RC staining was performed using Bright-
Vision. 3-Amino-9-ethylcarbazole; Vector Laboratories,
Burlingame, CA, USA) was used as chromogen. Slides
were counterstained with Gill’s haematoxylin (Klinipath,
Duiven, the Netherlands) and mounted in Kaiser’s glycerol
gelatin (Merck, Darmstadt, Germany).
The intensity of staining was analysed by digital image
analysis in a blinded fashion using a Syndia algorithm on
a Qwin-based analysis system (Leica, Cambridge, UK) as












































































































































Figure 1 (See legend on next page.)
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Figure 1 Expression of interleukins 17A and 17F and their receptors in synovial tissue. The expression of interleukin 17A (IL-17A), IL-17F,
IL-17RA and IL-17RC in rheumatoid arthritis (RA), osteoarthritis (OA), psoriatic arthritis (PsA) and noninflamed synovial tissue was determined by
immunohistochemistry using monoclonal antibodies. For each marker, a representative microscopic picture is given in synovial tissue of a RA
patient (left) and a PsA patient (right) (A). The intensity of staining was analysed using digital image analysis, and levels were compared between
the noninflammatory and arthritis groups using a Mann-Whitney U test (B) and between OA, PsA and RA patients using a Kruskal-Wallis test with
post hoc Dunn’s multiple-comparisons tests (C). *P < 0.05. IOD, Integrated optical density.
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tegrated optical density per square millimetre of tissue
[34].Colocalisation using immunofluorescence
Colocalisation studies between IL-17 and cell-specific
markers were performed using a sequential double-
immunofluorescence staining method. Frozen tissue
sections were thawed and air-dried at room temperature
and subsequently fixed in acetone. After washing in
PBS, primary antibody (anti-IL17A or anti-IL-17F) was
applied and incubated overnight at 4°C. As a negative
control, sections were incubated with isotype-matched
immunoglobulins. After incubation, bound primary
antibodies were detected using isotype-specific Alexa
Fluor 594–conjugated or Alexa Fluor 488–conjugated
antibodies (Molecular Probes Europe, Leiden, the
Netherlands). Subsequently, sections were blocked
with 10% normal mouse serum to prevent nonspecific
binding. Cell-specific antibodies were applied and incu-
bated for 1 hour at room temperature, after which the
staining was developed using streptavidin-Alexa Fluor
594–, streptavidin-Alexa Fluor 633– or isotype-specific
Alexa Fluor 594– or Alexa Fluor 488–conjugated anti-
bodies (Molecular Probes Europe). After staining, the
slides were mounted with VECTASHIELD HardSet
containing 4′,6-diamidino-2-phenylindole dihydrochloride
(Vector Laboratories) for nuclear counterstaining. Coloca-
lisation was visualised using a TCS SP2 spectral confocal
and multiphoton system (Leica Microsystems, Wetzlar,
Germany).Statistical analysis
GraphPad Prism software (V.5; GraphPad Software, La
Jolla, CA, USA) and SPSS version 18.0.2 software
(SPSS, Chicago, IL, USA) were used for statistical
analysis. Nonnormally distributed data are presented
as median (interquartile range). Differences between
study groups were analysed using the Kruskal-Wallis test
with post hoc Dunn’s multiple comparisons test or the
Mann Whitney U test where appropriate. Correlations
were assessed with the Spearman’s rank-order correlation
coefficients. P-values below 0.05 were considered statisti-
cally significant.Results
Levels of IL-17A were significantly increased in synovial
tissues of patients with inflammatory arthritis, but highly
variable between patients
We used monoclonal antibodies against IL-17A, IL-17F,
IL-17RA and IL-17RC to determine their protein expres-
sion in synovial tissue biopsies using IHC (Figure 1A). A
diffuse cytoplasmic staining pattern was observed for IL-
17A in the sublining as well as in the intimal lining layer
of the synovium. IL-17F showed a more cellular staining
pattern, mainly in the synovial sublining. In line with
their ubiquitous expression, both IL-17RA and IL-17RC
were abundantly present at high IL-17RC levels in the
intimal lining layer. Whereas the levels of IL-17F, IL-17RA
and IL-17RC were on average comparable between nonin-
flamed synovial tissues (n = 7) and the levels observed in
patients with inflammatory arthritis (n = 40), the levels of
IL-17A were significantly increased in patients with in-
flammatory arthritis (Figure 1B).
The expression levels of IL-17A and their receptors
were not different between RA, OA and PsA patients
(Figure 1C). This is in line with the results of the study
by Benham and colleagues, which showed no difference
in synovial IL-17 expression between RA, PsA and OA
patients, although those investigators did not (further)
stain for the different members of the IL-17 Family and
their receptors [35]. The levels of IL-17F were signifi-
cantly increased in PsA compared to OA patients.
Interestingly, the overall levels of IL-17RA were positively
correlated with IL-17F (r = 0.45, P = 0.001), but not with
IL-17A (r = 0.15, P = 0.36). In addition, the overall IL-17RC
level was positively correlated with both IL-17A and IL-17F
(r = 0.48, P = 0.005; and r = 0.39, P = 0.012, respectively). In
a subanalysis, similar correlations were observed for indi-
vidual patients within a group of the same diagnosis (data
not shown). This may suggest that targeting IL-17RC might
be a more effective treatment strategy through inhibition of
both the IL-17A and IL-17F pathways.
The baseline characteristics between the different
groups of patients were comparable, except for age and
swollen joint count 28 (SJC28). OA patients were sig-
nificantly older than the other groups. The RA patients
had more swollen joints compared to the PsA patients.
The expression levels of IL-17A, IL-17F, IL-17RA and
IL-17RC were not correlated with clinical parameters.
Figure 2 Colocalisation between interleukins 17A, 17F and cell-specific markers. The colocalisation between interleukin 17A (IL-17A) or IL-
17F and markers for T cells, neutrophils, mast cells, macrophages, blood vessels and lymphatics was examined using double-immunofluorescence
labelling and visualised by confocal microscopy. White arrowheads indicate colocalisation. Representative pictures are presented. Type 17 helper T
(Th17) cells were used to show that the IL-17A and IL-17F antibodies used can detect Th17-produced IL-17. Lyve-1, Lymphatic vessel endothelial
hyaluronan receptor 1; MCT, Mast cell tryptase; PNAd, Peripheral lymph node addressin; vWF, von Willebrand factor. Pictures illustrating the
separate channels for CD4, CD8, CD68 and CD163 staining with IL-17 are shown in Additional file 1: Figure S1 and Additional file 2: Figure S2.
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erythrocyte sedimentation rate (ESR) and C-reactive
protein (r = 0.41 and P = 0.040, r = 0.41 and P = 0.045,
respectively). The correlation with ESR was strongest inthe PsA patients (r = 0.50 and P = 0.028). Only the levels
of IL-17F showed a weak but statistically significant
negative correlation with age (r = −0.41, P < 0.005). We
cannot exclude the possibility that this may be explained
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the P-value was quite low.
Altogether, these immunohistochemical analyses re-
vealed a striking heterogeneous expression pattern for
IL-17A, IL-17F and their receptors in inflamed syno-
vium. Although some synovial tissues showed high ex-
pression levels, in other patients almost no expression
was observed. This variability may explain the variable
clinical responses observed in clinical trials in which IL-
17 was targeted (reviewed in [27,36]). In addition, low
levels of IL-17 may reflect the possible shift from Th17
to Th1 cells at sites of local inflammation [4,37].
Cellular sources of IL-17A and IL-17F in inflamed synovium
Conflicting data have been reported on the cellular
sources of IL-17A and IL-17F in inflamed synovia of pa-
tients with different forms of arthritis. In the first studies
showing IL-17 production and protein expression in RA
synovial tissue biopsies using IHC, researchers reported
lymphocytic morphology of IL-17-positive cells [12], and
IL-17A and IL-17F staining was especially prominent in
lymphocyte aggregates [12,38-41]. IL-17A-producing CD4+Figure 3 Retinoic acid receptor–related orphan receptor γt–positive c
nuclear expression of the IL-17-specific transcription factor retinoic acid rec
tissue biopsies (A). Immunofluorescence showed that RORγt-positive cells (
(IL-17A) (B) or IL-17F (C).T cells have also been observed in the synovial fluid of
RA patients [42,43] and PsA patients [35,41,44]. Later
reports suggested colocalisation of IL-17 with markers
for mast cells [45,46] and neutrophils [47] in RA syn-
ovial tissue. Also, in ankylosing spondylitis, cells of the
innate immune system appeared to be a major source of
IL-17 [48,49]. The conflicting observations may be the
result of technical difficulties in detecting IL-17 in
paraffin-embedded synovial tissue, the use of polyclonal
antibodies to detect IL-17, and clinical differences be-
tween patients studied.
We performed detailed double-immunofluorescence
studies to investigate colocalisation of IL-17A or IL-17F
and markers for T cells, neutrophils, mast cells and macro-
phages. In addition, because our IHC results indicated the
presence of IL-17A and IL-17F in vessel-like structures,
we included markers for blood vessels and lymphatics. To
investigate whether the origin of IL-17A or IL-17F was dif-
ferent between RA, PsA and OA patients, synovial tissue
was stained from at least five different patients per diagno-
sis for the analysis of T cells, mast cells and macrophages.
For the other markers, we stained synovial tissues from atells in synovium. Immunohistochemistry showed an abundant
eptor–related orphan receptor γt (RORγt) (shown in red) in synovial
red nuclei) in synovial tissue were indeed positive for interleukin 17A
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confocal pictures are shown in Figure 2, Additional file 1:
Figure S1 and Additional file 2: Figure S2.
The frequency of CD15+ neutrophils in the synovium
was very low, and no colocalisation with IL-17A or IL-17F
was observed, suggesting that, in inflamed synovium, these
cells do not contribute to IL-17 production. CD4+ and
CD8+ T cells stained positive for IL-17A, and few cells
were positive for IL-17F. CD68+ and CD163+ macro-
phages showed colocalisation with IL-17A and, to a lesser
extent, with IL-17F. We only occasionally observed coloca-
lisation between MCT +mast cells and IL-17A or IL-17F,
mainly in PsA patients. Interestingly, we observed IL-17A-
and IL-17F-positive cells in vWF+, CD31+ and PNad +
blood vessels, as well as in Lyve-1 positive lymphatics.
Overall, no clear differences were observed between
RA, PsA and OA patients.
Colocalisation between IL-17 and specific cell markers
does not necessarily mean that IL-17 is produced by this
specific cell. Because the used IL-17 antibodies are non-
neutralising, we may detect IL-17 bound to its receptor,
which probably is the case in the IL-17-positive blood
vessels and lymphatics. To investigate whether IL-17 can
be produced by infiltrated cells in the synovium, we
stained for the transcription factor RORγt, which is es-
sential for IL-17 production. RORγt-positive cells were
abundantly present throughout the synovial tissues
(Figure 3A). As expected, most RORγt-positive cells
were CD3+ T cells (data not shown). More importantly,
RORγt nuclear staining colocalised with IL-17A and IL-
17F around the same cell, indicating local cytokine pro-
duction (Figures 3B and C).Discussion
We observed increased IL-17A expression in synovial tis-
sues from inflammatory arthritis patients compared with
noninflamed control synovium, supporting the concept
that IL-17 is a key cytokine in chronic inflammatory
arthritis. The levels of IL-17A, IL-17F and their recep-
tors are comparable, on average, between RA, PsA and
OA. Using double-immunofluorescence we show that T
cells and macrophages can contribute to the production
of IL-17A and IL-17F. Colocalisation between the tran-
scription factor RORγt and IL-17 indicate local cytokine
production. The heterogeneous expression patterns of
IL-17A, IL-17F and their receptors could perhaps
explain the limited clinical response observed in clinical
trials in which IL-17A in arthritis is targeted, as many
patients exhibit very low IL-17 levels at the site of
inflammation. These results suggest that patient stratifi-
cation based on IL-17 expression may be required to
demonstrate the beneficial effect of anti-IL-17 therapy
in subsets of patients.Additional files
Additional file 1: Figure S1. Colocalisation between IL-17A and CD4,
CD8, CD68 and CD163 was examined using double-immunofluorescence
labelling and visualized by confocal microscopy. Representative pictures
showing separate channels are presented.
Additional file 2: Figure S2. Colocalisation between IL-17F and CD4,
CD8, CD68 and CD163 was examined using double-immunofluorescence
labelling and visualized by confocal microscopy. Representative pictures
showing separate channels are presented.
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